Bayer reported 2% year-on-year sales growth on a currency- and portfolio-adjusted basis, and EBITDA before special items rose 7%. Management raised full-year guidance for EBITDA before special items to EUR 9.8 billion-EUR 10.3 billion, up from EUR 9.6 billion-EUR 10.1 billion.
Several drugs, including recently launched cancer drugs and late-stage pipeline asset asundexian, hold potential for further gains and have relatively steady pricing power partly based on excellent clinical data.
Generic Xarelto and Eylea entry in various territories over the near term will put accelerating pressure on Bayer's revenue and profit margins.
|
Metric
|
BAYRY
|
BASFY
|
PFE
|
|---|---|---|---|
Price/Earnings (Normalized) | 12.14 | 20.54 | 13.80 |
Price/Book Value | 1.71 | 1.24 | 1.92 |
Price/Sales | 1.06 | 0.71 | 2.70 |
Price/Cash Flow | 22.58 | 7.94 | 11.63 |
|
Metric
|
BAYRY
|
BASFY
|
PFE
|
|---|---|---|---|
Quick Ratio | 0.93 | 1.14 | 1.00 |
Current Ratio | 1.35 | 1.92 | 1.42 |
Interest Coverage | 0.44 | 3.37 | 2.39 |
|
Metric
|
BAYRY
|
BASFY
|
PFE
|
|---|---|---|---|
Return on Assets (Normalized) | 4.19% | 0.17% | 8.49% |
Return on Equity (Normalized) | 15.75% | 0.39% | 19.73% |
Return on Invested Capital (Normalized) | 8.54% | 0.86% | 12.71% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|&$@RKGP | LOCK|#r | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|tN!jBf^ | LOCK|@&R | $641B | |||
| AbbVie Inc
ABBV
| LOCK|!B#j!q | LOCK|H%R | $506B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|?%!<LJc@ | LOCK|s< | $382B | |||
| Merck & Co Inc
MRK
| LOCK|!vZ$^QG | LOCK|zQ^ | $357B | |||
| Novartis AG ADR
NVS
| LOCK|z%N&#>?% | LOCK|H<< | $303B | |||
| AstraZeneca PLC
AZN
| LOCK|L#$PY!Qr | LOCK|Ft! | $286B | |||
| Amgen Inc
AMGN
| LOCK|>#z>lBqB | LOCK|?r | $249B | |||
| Gilead Sciences Inc
GILD
| LOCK|@!@nnH | LOCK|MQ! | $208B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|?ZZ>Cy | LOCK|?<Y | $178B |
United States